Freelite®

Freelite provides prognostic information to identify patients with a higher risk of a poor outcome. These patients may need more frequent monitoring. Serum k and λ free light chains (FLCs) can predict outcomes, both from baseline tests at diagnosis and during monitoring, in many symptomatic and asymptomatic plasma cell disorders.

International Myeloma Working Group guidelines recommend the use of the serum FLC assay in prognosis - “The serum FLC assay should be measured at diagnosis for all patients with MGUS, smoldering or active multiple myeloma, solitary plasmacytoma and AL amyloidosis.”

Freelite risk stratification allows identification of patient sub groups that could benefit from different care:

• MGUS (Monoclonal Gammopathy of Undetermined Significance)
• Smouldering Multiple Myeloma
• Multiple Myeloma
• AL amyloidosis

Risk factors:

• Abnormal FLC ratio
• Serum monoclonal protein >15g/L
• IgA or IgM monoclonal protein type

To optimise counselling and follow-up, IMWG guidelines recommend MGUS patients should be risk stratified at diagnosis using Freelite (alongside SPE/IFE). By identifying those at low risk (~40%), Freelite saves time, money and patient discomfort as fewer clinic visits and tests are needed.

Hevylite pair suppression is also an independent risk factor for MGUS progression.